These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 38842787)
21. Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks. Taghdiri A Egypt Heart J; 2024 Jun; 76(1):71. PubMed ID: 38849680 [TBL] [Abstract][Full Text] [Related]
22. Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma. Bini I; Asaftei SD; Riggi C; Tirtei E; Manicone R; Biasin E; Basso ME; Agnoletti G; Fagioli F Cardiol Young; 2017 Nov; 27(9):1815-1822. PubMed ID: 28780919 [TBL] [Abstract][Full Text] [Related]
23. Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka. Sandamali JAN; Hewawasam RP; Fernando MACSS; Jayatilaka KAPW BMC Cancer; 2023 Mar; 23(1):210. PubMed ID: 36870959 [TBL] [Abstract][Full Text] [Related]
24. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870 [TBL] [Abstract][Full Text] [Related]
25. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors. Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058 [TBL] [Abstract][Full Text] [Related]
26. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Henriksen PA Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634 [TBL] [Abstract][Full Text] [Related]
27. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Scully RE; Lipshultz SE Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816 [TBL] [Abstract][Full Text] [Related]
28. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients. Stansfeld A; Radia U; Goggin C; Mahalingam P; Benson C; Napolitano A; Jones RL; Rosen SD; Karavasilis V Expert Opin Pharmacother; 2022 Oct; 23(14):1641-1650. PubMed ID: 36102190 [TBL] [Abstract][Full Text] [Related]
29. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial. Hao W; Liu S; Qin Y; Sun C; Chen L; Wu C; Bao Y Trials; 2017 Aug; 18(1):386. PubMed ID: 28830541 [TBL] [Abstract][Full Text] [Related]
30. Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging. Jong J; Pinney JR; Packard RRS Front Cardiovasc Med; 2022; 9():919719. PubMed ID: 35990941 [TBL] [Abstract][Full Text] [Related]
31. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Ghigo A; Li M; Hirsch E Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775 [TBL] [Abstract][Full Text] [Related]
32. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Creutzig U; Diekamp S; Zimmermann M; Reinhardt D Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582 [TBL] [Abstract][Full Text] [Related]
33. Heart Failure in Relation to Anthracyclines and Other Chemotherapies. Agunbiade TA; Zaghlol RY; Barac A Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684 [TBL] [Abstract][Full Text] [Related]
34. Current views on anthracycline cardiotoxicity. Mele D; Nardozza M; Spallarossa P; Frassoldati A; Tocchetti CG; Cadeddu C; Madonna R; Malagù M; Ferrari R; Mercuro G Heart Fail Rev; 2016 Sep; 21(5):621-34. PubMed ID: 27230651 [TBL] [Abstract][Full Text] [Related]
35. [Treatment-related cardiotoxicity in childhood cancer survivors: Risk factors and follow-up]. Fresneau B; Fayech C; Butel T; Haddy N; Valteau-Couanet D; Ou P Rev Med Interne; 2017 Feb; 38(2):125-132. PubMed ID: 27639916 [TBL] [Abstract][Full Text] [Related]
36. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines. Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778 [TBL] [Abstract][Full Text] [Related]
37. Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions. Liu C; Chen H; Guo S; Liu Q; Chen Z; Huang H; Zhao Q; Li L; Cen H; Jiang Z; Luo Q; Chen X; Zhao J; Chen W; Yang PC; Wang L Biomed Pharmacother; 2023 Oct; 166():115373. PubMed ID: 37647693 [TBL] [Abstract][Full Text] [Related]
38. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors. Sadurska E Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787 [TBL] [Abstract][Full Text] [Related]
39. [Possibilities of modern echocardiographic technologies in the early diagnosis of the cardiotoxic effect of chemotherapy drugs anthracycline series in cancer patients]. Vasyuk YA; Nesvetov VV; SHkolnik EL; Fursov SA; Shkolnik LD; Gendlin GE; Emelina EI Kardiologiia; 2017 Apr; 57(S4):31-37. PubMed ID: 29466180 [TBL] [Abstract][Full Text] [Related]
40. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)]. Saganelidze K; Kavtaradze N Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]